SCM
CNTB icon

Stonepine Capital Management’s Connect Biopharma Holdings CNTB Stock Holding History

Stonepine Capital Management’s Portfolio CNTB Stock Details CNTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$867K Buy
364,254
+54,254
+18% +$132K 0.49% 48
2026
Q1 		$812K Buy
+310,000
New +$808K 0.33% 44

Other funds holding CNTB

Ikarian Capital
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Boothbay Fund Management
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ADAR1 Capital Management
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
Silverarc Capital Management
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.65% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $192M AUM 23.02% 1-Year Est. Return
DMKJ
David M. Knott Jr $189M AUM 67.72% 1-Year Est. Return

Stonepine Capital Management's CNTB Position: Q2 2026 in Review

Stonepine Capital Management increased its Connect Biopharma Holdings (CNTB) stake by 18% in Q2 2026, buying an estimated $132K and bringing the position to 364,254 shares worth $867K. The position accounts for 0.49% of the portfolio, ranked #48.

Stonepine Capital Management first reported a position in CNTB in Q1 2026 and has held it in 2 quarters since. 56 funds tracked by Wall St. Rank hold CNTB as of Q2 2026.

  • Stonepine Capital Management held 364,254 shares of Connect Biopharma Holdings worth $867K as of Q2 2026.
  • Stonepine Capital Management bought 54,254 Connect Biopharma Holdings shares in Q2 2026, an estimated $132K.
  • Connect Biopharma Holdings made up 0.49% of Stonepine Capital Management's portfolio in Q2 2026, its #48 holding.
  • Stonepine Capital Management first reported a position in Connect Biopharma Holdings in Q1 2026 and has held it in 2 quarters since.
  • 56 funds tracked by Wall St. Rank held Connect Biopharma Holdings as of Q2 2026.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.